| Literature DB >> 28723406 |
Laura Ferrari1, Mélanie Claps1, Salvatore Grisanti1, Alfredo Berruti2.
Abstract
Mitotane and chemotherapy with etoposide, doxorubicin, and cisplatin plus mitotane (EDP-M) are the only therapies with demonstrated efficacy in advanced adrenocortical carcinoma. Prognostic and predictive factors are needed to identify patients who could obtain the best benefit from these treatments. Despite the strong rationale for their use, clinical trials on molecular targeted therapies have failed to demonstrate that these drugs are efficacious in the management of this extremely rare disease.Entities:
Year: 2015 PMID: 28723406 DOI: 10.1016/j.euf.2015.06.005
Source DB: PubMed Journal: Eur Urol Focus ISSN: 2405-4569